- AuthorisedTherapeutic confirmatory (Phase III)
A prospective, randomized, and controlled study comparing two treatment strategies (Dose REduction of Antipsychotics vs. Maintenance treatment) in patients with schizophrenia spectrum disorder after Stratification based on patients’ psychotic PHENotype: a personalized medicine approach
This study compares two ways to treat schizophrenia: either continuing usual medication or carefully reducing it. It aims to see which approach helps patients live better lives by checking their daily function over two years. Researchers hope to find a more personalised treatment.
For: Patient with a diagnosis of schizophrenia spectrum disorder (SSD): schizophrenia · schizophreniform · schizoaffective disorder or brief psychotic episode according to DSM-5France - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
AMEND - Add-on MEmaNtine to Dopamine modulation to improve negative symptoms at first psychosis
This study looks at whether adding a medicine called memantine to usual treatment can help young people experiencing their first episode of psychosis. Researchers want to see if it improves 'negative symptoms' like lacking motivation or social withdrawal, over 12 weeks.
For: First episode psychosis · ICD-10: F20.xDenmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study.
This study looks at whether a cannabis-derived medicine (CBD) can help young people with temporary mental health problems caused by substance use. It aims to see if CBD can reduce the chances of them using cannabis again after six months, compared to a dummy treatment.
For: Substance-Induced PsychosisItaly